Faeth Therapeutics Inc. (FTH)
Faeth Therapeutics Inc. (FTH) Stock Price, Analysis & Data
| Bid | 31.8 |
| Market Cap | 816.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -195.53M |
| Beta | -0.31 |
| EPS (ttm) | -60.86 |
| PE Ratio (ttm) | n/a |
| Forward PE | -6.37 |
| P/B (ttm) | 4.72 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 3, 2026 |
| Ask | 35 |
| Volume | 147,557 |
| Avg. Volume (20D) | 195,129 |
| Open | 33.42 |
| Previous Close | 33.11 |
| Day's Range | 30.75 - 33.42 |
| 52-Week Range | 7.45 - 37.90 |
| Analyst | Strong Buy |
| Price Target | 55 (74.66%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FTH
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The...
Financial Performance
In 2025, Faeth Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -21.09M, a decrease of -30.08%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for FTH stock is "Strong Buy". The 12-month stock price forecast is 55, which is upside of 74.66% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
